Nasdaq: PTCT
PTC Therapeutics insiders
The officers, directors and 10% owners of PTC Therapeutics, Inc. who hold the most stock, valued at the live PTCT price.
$58.33
PTCT today −$1.9M (−3.16%)
Market closed. Prices as of Nov 19, 4:04 PM ET
- Ranked insiders
- 5
- Their PTCT stock
- $55.5M
- Market value
- $4.87B
- Held by ranked insiders
- 1.14%
Insiders by value of PTCT holdings
SEC ownership page| # | Insider | Role | Shares | Value | Of company | Overall rank |
|---|---|---|---|---|---|---|
| 1 | Matthew B. Klein | CHIEF EXECUTIVE OFFICER | 383,868 | $22.4M | 0.46% | 4708th |
| 2 | Stuart Walter Peltz | CHIEF EXECUTIVE OFFICER | 260,593 | $15.2M | 0.31% | 6374th |
| 3 | Michael Schmertzler | Director | 163,266 | $9.5M | 0.20% | 2218th |
| 4 | Mark Elliott Boulding | EXEC. VP AND CLO | 105,272 | $6.1M | 0.13% | 12562nd |
| 5 | Emily Luisa Hill | CHIEF FINANCIAL OFFICER | 38,925 | $2.3M | <0.1% | 12564th |
Only insiders worth at least $5 million in listed stock are ranked. Holdings come from each insider's latest Form 3, 4 or 5 for PTC Therapeutics; see each profile for the filing.